Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids  by Ahuja, Tejinder S. & Weiss, Vasanta P.
Letters to the Editor802
Correspondence to Kostas Sombolos, M.D., Vas Olgas 82, 546 43, Tsakiris ask in this issue of Kidney International whether
Thessaloniki, Greece. the time has come to accept “this type of market on
E-mail: sobolos@spark.net.gr
kidney transplantation.” I say no, but I do think that
other financial incentives will not necessarily lead down
REFERENCES such slippery slope.
1. Gjertson DW, Cecka JM: Living unrelated donor kidney trans-
plantation. Kidney Int 58:491–499, 2000 Kristian T. Schafernak
2. Schafernak KT: Organ commerce revisited. Kidney Int 58:901, 2000 Chicago, IL, USA
Correspondence to Kristian T. Schafernak, M.D., Rush Medical Col-Reply from the author
lege, 2026 West Fletcher Street, Chicago, IL 60618-6418, USA.
Plotting supply against demand is in many ways the ar- E-mail: KSchafernak@rushu.rush.edu
chetypal battle between good and evil in organ trans-
plantation. Enter ethics and a little common sense and REFERENCES
sometimes the “goodness” of supply, by virtue or vice 1. Schafernak KT: Organ commerce revisited. Kidney Int 58:901,2000
of its means, comes into question. For this reason, the 2. 1999 Annual Report of the U.S. Scientific Registry for Transplant
Recipients and the Organ Procurement and Transplantation Net-battle becomes less archetypal. What society finds ethi-
work: Transplant Data: 1989–1998. U.S. Department of Health and
cally palatable dictates the limits of transplantation Human Services, Health Resources and Services Administration,
Office of Special Programs, Division of Transplantation, Rockville,policy.
MD; UNOS, Richmond, VAIn my Letter to the Editor, I reported the attempts in
3. Chugh KS, Jha V: Commerce in transplantation in Third World
August 2000 of several would be organ donors to bring countries. Kidney Int 49:1181–1186, 1996
4. Nelson EW, Childress JE, Perryman J, Robards V, Rowan A,their kidneys into the e-commerce marketplace [1]. In
Seely MS, Sterioff S, Rovelli Swanson M: Financial incentivesaddition, I sought to stimulate reconsideration of finan-
for organ donation: a report of the UNOS Ethics Committee: Pay-
cial incentives to encourage organ donation because reli- ment Subcommittee. URL: http://www.unos.org/Resources/bioethics_
whitepapers_finance.htm [Accessed October 23, 2000]ance strictly on altruism fails for an increasing number
5. Gjertson DW, Cecka JM: Living unrelated donor kidney trans-of people each year in the United States. In 1998, 4,860
plantation. Kidney Int 58:491–499, 2000
people died waiting for any organ, 2,307 of whom were
waiting for kidneys [2]. I did not suggest support of
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I also compared the recent attempts at electronic or- Cohort study of the treatmentgan commerce to historical Third World organ com-
merce, as reported by Chugh and Jha [3]. I predict that of severe HIV-associatedallowing a market to operate without regulation would
result, like it did in India, in a reverse “Robin Hood” nephropathy withphenomenon where organs are essentially stolen from
the poor and given to the rich. corticosteroidsThere are ways to tie financial incentives to organ
donation while remaining close to the spirit of donation To the Editor: We read the article in a recent issue
and preserving fair allocation, including death benefits of Kidney International by Eustace et al with great inter-
(like estate tax deductions or funeral expense reimburse- est [1]. The authors reported 18 episodes of infection
ment) and prospective sale, also called “donor insur- in a corticosteroid-treated group of patients with HIV-
ance” or a “futures market” whereby direct payment is associated nephropathy (HIVAN) the majority of which
made to beneficiaries upon death and subsequent har- were life-threatening, compared to 8 such episodes in the
vest. Only about one third of the 10,000 to 12,000 poten- non-corticosteroid–treated group. Despite these results,
tial cadaveric donors per year donate organs [4]. The the authors suggested that the therapy with corticoste-
remaining constitute an excellent resource for bridging roids is relatively safe. They based their conclusion on the
the gap between supply and demand. presumption that if non-corticosteroid–treated patients
The data presented by Gjertson and Cecka clearly were followed up for a similar length of time as the
show that living unrelated donor kidney transplantation corticosteroid-treated patients, the incidence of infec-
has a superior outcome to cadaveric donation [5]. This tions would be the same in both groups. However, this
makes paid living donation or a free market for organ may not be true in the era of highly active antiretroviral
transplantation particularly seductive. Sombolos and therapy (HAART), which has dramatically improved
survival of HIV-infected hemodialysis patients [2]. When
a clinician reaches a crossroad in treating patients with
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We completely agree with the authors that HAART
Reply from the authorsand angiotensin-converting enzyme (ACE) inhibitors
We thank Drs. Ahuja and Weiss for their comments.should be the first-line therapy for patients with HIVAN.
In our study, given the unequal follow-up period inOne very important intervention in preserving the long-
the corticosteroid-treated and non-corticosteroid–treatedterm renal function of patients with HIVAN is an early
groups, it is misleading to simply compare the numberdiagnosis and treatment with HAART and ACE inhibi-
of observed events, such as hospitalizations. Instead, ittors. In a previous study we screened 557 asymptomatic
is essential to compare the observed event rates (numberHIV-infected patients for HIVAN. Of the 10 patients
of events per unit of time of follow-up). Thus, in ourwith HIVAN two were diagnosed at an early stage of
study the actual observed (not extrapolated) serious in-the disease and were treated with HAART and ACE
fection rate was similar, and not significantly different,inhibitors [3]. Two years after the initial diagnosis and
in both the corticosteroid-treated and the non-corticoste-treatment, both patients have stable renal function (ab-
roid–treated groups, at 1 per 2.6 patient-months of fol-stract; Memon A, J Am Soc Nephrol 11:A0491, 2000).
low-up and 1 per 2.3 patient-months of follow-up, respec-We agree with Eustase et al that corticosteroid therapy
tively. We suspect that with the concomitant use of highlyshould be limited strictly to those patients with HIVAN
active antiretroviral therapy (HAART) the incidence ofwho have rapidly deteriorating renal functions and high
infection may have been reduced in the corticosteroid-CD4 counts.
treated as well as in the non-corticosteroid–treated
group. In the absence of any data, however, this possibil-Tejinder S. Ahuja and Vasanta P. Weiss
Galveston, Texas, USA ity remains purely speculative. We agree with Ahuja and
Weiss that early detection and treatment are essential
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